Browse EX-10 agreements

STAAR SURGICAL COMPANY

AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN

STOCK OPTION GRANT NOTICE

STAAR Surgical Company, a Delaware corporation, (the “Company”), pursuant to its Amended and Restated Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (“Participant”), in consideration of the mutual agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, an option to purchase the number of shares of the Company’s Common Stock (“Stock”), set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein, as well as in the Plan and the Stock Option Agreement attached hereto as Exhibit A(the “Agreement”), each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement. A Prospectus regarding the Stock is available at https://staarus.sharepoint.com/sites/STAARNET.

…

STAAR SURGICAL COMPANY

AMENDED AND RESTATED OMNIBUS EQUITY INCENTIVE PLAN

STOCK OPTION GRANT NOTICE

STAAR Surgical Company, a Delaware corporation, (the “Company”), pursuant to its Amended and Restated Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (“Participant”), in consideration of the mutual agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, an option to purchase the number of shares of the Company’s Common Stock (“Stock”), set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein, as well as in the Plan and the Stock Option Agreement attached hereto as Exhibit A(the “Agreement”), each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement. A Prospectus regarding the Stock is available at https://staarus.sharepoint.com/sites/STAARNET.

…

MASTECHDIGITAL,INC.

2008STOCKINCENTIVEPLAN

(asamendedandrestated)

RESTRICTEDSTOCK UNIT (RSU) AGREEMENT

THIS RESTRICTED STOCK UNIT (RSU) AGREEMENT (this “Agreement”) is made as of the date set forth on Schedule A hereto (the “Grant Date”) by and between Mastech Digital, Inc., a Pennsylvania corporation (the “Corporation”), and the person named on Schedule A hereto (the “Grantee”).

WHEREAS, Grantee is a valuable employee of the Corporation or one of its subsidiaries (each, an “Affiliate”) and the Corporation considers it desirable and in its best interest that Grantee be given an inducement to acquire a proprietary interest in the Corporation and an incentive to advance the interests of the Corporation by granting the Grantee restricted stock units representing the right to receive shares of common stock, par value $.01 per share, of the Corporation (the “Stock”); and

…

AMENDING AGREEMENT

(Amendment to Loan Agreement)

THIS AMENDING AGREEMENT is dated for reference August 5, 2026 (this “Amendment”), and is made

BETWEEN:

RAIN COMMUNICATIONS CORP., a company registered in the Province of British Columbia

(the “Lender”);

AND:

BLUE LINE HOLDINGS INC., a company registered in the State of Colorado

(the “Borrower”).

** **

WHEREAS the Lender and the Borrower entered into a loan agreement dated for reference December 15, 2025 (the “Loan Agreement”), pursuant to which the Lender advanced to the Borrower the principal sum of Twenty-Five Thousand United States Dollars (US $25,000) (the “Loan”);

** **

AND WHEREAS the Loan Agreement provides that the term of the Loan ends, and the Loan is repayable, on or before June 30, 2026;

** **

AND WHEREAS the Lender and the Borrower wish to amend the Loan Agreement to extend the term of the Loan and the repayment date, and the Borrower has agreed to issue additional common shares to the Lender in consideration of such extension, on the terms set out in this Amendment;

** **

…

LOAN AGREEMENT

** **

THIS AGREEMENT, dated for reference August 5, 2026, is made

BETWEEN:

MICHAEL MCGRATH

(the “Lender”);

AND:

BLUE LINE HOLDINGS INC., a company registered in the State of Colorado

(the “Borrower”)

WHEREAS the Borrower wishes to borrow and the Lender is willing to lend to the Borrower Fifteen Thousand United States Dollars (US $15,000) on the terms of this Agreement.

NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the premises and the mutual covenants and agreements hereinafter set forth, the parties hereto agree as follows:

1.	DEFINITIONS

Where used in this Agreement, the following words and phrases shall have the following meaning:

…

AMENDING AGREEMENT

(Amendment to Loan Agreement)

THIS AMENDING AGREEMENT is dated for reference August 5, 2026 (this “Amendment”), and is made

BETWEEN:

KILKEEL CAPITAL CORP., a company registered in the Province of Alberta (the “Lender”);

AND:

BLUE LINE HOLDINGS INC., a company registered in the State of Colorado (the “Borrower”).

WHEREAS the Lender and the Borrower entered into a loan agreement dated for reference December 15, 2025 (the “Loan Agreement”), pursuant to which the Lender advanced to the Borrower the principal sum of Twenty-Five Thousand United States Dollars (US $25,000) (the “Loan”);

AND WHEREAS the Loan Agreement provides that the term of the Loan ends, and the Loan is repayable, on or before June 30, 2026;

AND WHEREAS the Lender and the Borrower wish to amend the Loan Agreement to extend the term of the Loan and the repayment date, and the Borrower has agreed to issue additional common shares to the Lender in consideration of such extension, on the terms set out in this Amendment;

…

**PRIVATE AND CONFIDENTIAL **

July 16, 2026

Revised June 19, 2026

Saurabh Sinha

[***]

Dear Saurabh:

We are pleased to present the following offer of employment with Arteris, Inc. (“Arteris” or the “Company”). This letter will summarize and confirm the details of our offer for you to join Arteris, in the position of Chief Financial Officer, commencing on or about September** 2, 2026 (the date you actually commence employment, the “Start Date”), **and reporting to **Charlie Janac, CEO. **You will perform the duties and responsibilities of this position, as well as additional duties and responsibilities as Arteris assigns to you from time to time.

…

…

…

…

OMNIBUS AMENDMENT AND TERMINATION AGREEMENT

This Omnibus Amendment and Termination Agreement (this “Termination”) is entered into effective as of August 5, 2026 (the “Effective Date”) by and among Ensysce Biosciences, Inc., a Delaware corporation on behalf of itself and its subsidiaries (the “Company”) and 3i, LP (“3i” and together with the Company, the “Parties”), whose signatures are set forth on the signature pages hereto.

RECITALS

WHEREAS, the Company wishes to acquire 100% of the outstanding equity interests of Cy Biopharma, Inc., a Delaware corporation (together with its subsidiaries, “Target”) for shares of common stock, par value $.0001 (“Common Stock”) and Series C Preferred Stock, par value $.0001 (“Series C Preferred Stock”) of the Company (the “Transaction”), with the date and time that the Transaction occurs to be referred to as the “Closing” for purposes of this Termination;

…

** **

Exhibit 10.3

** **

FORM OF REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is dated as of August 5, 2026, by and between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and the undersigned signatories hereto.

This Agreement is made in connection with that Agreement and Plan of Merger, dated as of the date hereof, by and among the Company, Cy Biopharma, Inc., a Delaware corporation (“Cy Biopharma”), and certain other parties thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Merger Agreement”), whereby as consideration for the transactions contemplated by the Merger Agreement (collectively, the “Merger”), the Company has agreed to issue shares of the Company’s Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Preferred Shares”), to the equityholders of Cy Biopharma.

…